{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00889460",
      "orgStudyIdInfo": {
        "id": "VO58.07 DK"
      },
      "organization": {
        "fullName": "Stallergenes Greer",
        "class": "INDUSTRY"
      },
      "briefTitle": "Safety and Tolerability Study of rBet v1 SLIT Tablets",
      "officialTitle": "Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen"
    },
    "statusModule": {
      "statusVerifiedDate": "2009-04",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2007-11"
      },
      "primaryCompletionDateStruct": {
        "date": "2008-04",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2008-04",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2009-04-28",
      "studyFirstSubmitQcDate": "2009-04-28",
      "studyFirstPostDateStruct": {
        "date": "2009-04-29",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2009-04-28",
      "lastUpdatePostDateStruct": {
        "date": "2009-04-29",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "oldNameTitle": "Bruno ROBIN",
        "oldOrganization": "Stallergenes S.A."
      },
      "leadSponsor": {
        "name": "Stallergenes Greer",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Quintiles, Inc.",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to determine the safety and tolerability of several doses of r Bet v1 administered as sub-lingual tablets in subjects sensitised to birch pollen."
    },
    "conditionsModule": {
      "conditions": [
        "Birch Pollen-Related Rhinoconjunctivitis",
        "Rhinitis, Allergic, Seasonal"
      ],
      "keywords": [
        "rBet v 1",
        "Birch pollen allergy",
        "Sublingual Immunotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 55,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "1",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo group",
          "interventionNames": [
            "Biological: Placebo"
          ]
        },
        {
          "label": "2",
          "type": "EXPERIMENTAL",
          "description": "rBet v 1 tablets",
          "interventionNames": [
            "Biological: rBet v 1"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "rBet v 1",
          "description": "Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.",
          "armGroupLabels": [
            "2"
          ],
          "otherNames": [
            "rBet v 1.0101"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo",
          "description": "Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.",
          "armGroupLabels": [
            "1"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Local tolerability",
          "timeFrame": "Assessed every day over 2 weeks"
        },
        {
          "measure": "Global safety",
          "timeFrame": "Assessed every day over 2 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Immunological markers (IgE and IgG4)",
          "timeFrame": "Between selection and follow-up visit (up to 18 weeks)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* written consent\n* Male or female subject from 18 to 60 years old and in general good health\n* For woman of child bearing potential:\n* Symptoms of birch pollen induced allergic rhinitis for at least the last 2 years.\n* Sensitisation to birch pollen as demonstrated with a positive SPT to birch pollen and specific IgE level (birch pollen and r Bet v1) \\>0.70 kU/L at screening.\n* FEV1 at least of 80% of predicted values at screening.\n* Subject accepting to comply fully with the protocol.\n\nExclusion Criteria:\n\n* Past or current disease which as judged by the Investigator, may affect the outcome of this study.\n* History of life-threatening asthma,\n* Asthma requiring daily treatment (whatever the pharmaceutical class).\n* Pregnant or lactating woman.\n* Subject being treated with inhaled steroids within 4 weeks prior to screening visit or within 12 weeks prior to screening visit.\n* Subject who previously received desensitisation treatment to birch pollen and/or other betulaceae (e.g., hazel tree, alder) or who plan to start desensitisation treatment during this study.\n* Symptoms during the treatment phase due to a sensitivity to a second allergen.\n* Subjects treated with ongoing immunotherapy with another allergen",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "60 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Hans-Jorgen MALLING, Pr. MD",
          "affiliation": "National University Hospital - Copenhagen - DENMARK",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "National University Hospital - Allergy Unit 4222",
          "city": "Copenhagen",
          "zip": "2100",
          "country": "Denmark",
          "geoPoint": {
            "lat": 55.67594,
            "lon": 12.56553
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "type": "RESULT",
          "citation": "L. Winther, L.K. Poulsen, B. Robin, M. Mélac, H. Malling Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT) The Journal of Allergy and Clinical Immunology February 2009 (Vol. 123, Issue 2, Page S215)"
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D006255",
          "term": "Rhinitis, Allergic, Seasonal"
        }
      ],
      "ancestors": [
        {
          "id": "D065631",
          "term": "Rhinitis, Allergic"
        },
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}